Autism irritability drug trial ends early: what happened?
Symptom relief
Terminated
This study looked at the long-term safety of pimavanserin for treating irritability in children and teens (ages 5-17) with autism. It was an extension of an earlier 6-week study, lasting 52 weeks. The trial was terminated early, so results are limited.
Phase: PHASE2, PHASE3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated May 01, 2026 15:57 UTC